GT Biopharma (GTBP) Income from Continuing Operations (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Income from Continuing Operations of 2844000.0 for Q1 2026, down 6.12% year-over-year from 3029379.97 in Q1 2025, and up 84.61% quarter-over-quarter from 18478000.0 in Q4 2025.
GT Biopharma (GTBP) Income from Continuing Operations (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Income from Continuing Operations for 17 consecutive years, with 2844000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 6.12% year-over-year to 2844000.0; the TTM figure through Mar 2026 stood at 51824000.0 (up 58.83% YoY), while the FY2025 annual figure was 153405000.0, down 21.61% from the prior year.
- Income from Continuing Operations rose to 2844000.0 in Q1 2026 per GTBP's latest filing, from 18478000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2680000.0 in Q1 2025 and bottomed at 220014000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 34120648.82 across 5 years, with a median of 3801000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 4922.0% — and 2023, when it jumped 98.26%.
- GT Biopharma's Income from Continuing Operations stood at 114699000.0 in 2022, then surged by 97.43% to 2948000.0 in 2023, then sank by 3831.07% to 115888000.0 in 2024, then soared by 84.06% to 18478000.0 in 2025, then surged by 84.61% to 2844000.0 in 2026.
- Business Quant data shows GTBP's Income from Continuing Operations at 2844000.0 in Q1 2026, 18478000.0 in Q4 2025, and 3627000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | -2.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.84 Mn |
| Dec 31, 2025 | -18.48 Mn |
| Sep 30, 2025 | -3.63 Mn |
| Jun 30, 2025 | -26.88 Mn |
| Mar 31, 2025 | -2.68 Mn |
| Dec 31, 2024 | -115.89 Mn |
| Sep 30, 2024 | -3.51 Mn |
| Jun 30, 2024 | -3.80 Mn |
| Mar 31, 2024 | -2.95 Mn |
| Dec 31, 2023 | -2.95 Mn |
| Sep 30, 2023 | -3.00 Mn |
| Jun 30, 2023 | -3.83 Mn |
| Mar 31, 2023 | -3.71 Mn |
| Dec 31, 2022 | -114.70 Mn |
| Sep 30, 2022 | -26.02 Mn |
| Jun 30, 2022 | -220.01 Mn |
| Mar 31, 2022 | -25.17 Mn |
| Dec 31, 2021 | -18.19 Mn |
| Sep 30, 2021 | -5.92 Mn |
| Jun 30, 2021 | -4.38 Mn |